A new Guide targeting potential life sciences investors for life sciences companies has been launched to build understanding of the unique life sciences sector to increase quantity and quality of investment in life sciences companies.
The Guide to Life Sciences Investing (the Guide) was developed for investors with little or no experience in the sector and outlines the factors particular to life sciences companies that potential investors should consider. It builds on general investment guidance and aims to equip potential investors with knowledge of the basic operations and products of life sciences companies, including the terminology, time lines and regulatory frameworks in the sector, as well as how securities trade on the market.
As part of an initiative aimed at increasing the competitiveness of Australian life sciences research and commercialisation in the global marketplace, AusBiotech is actively educating potential investors in life sciences companies about the unique ecosystem, particularly in the medical technology and pharmaceuticals (MTP) sector in Australia.
There has been an increase in investment into life sciences companies and technologies in recent years. Yet investor hesitancy remains, as information regarding the sector is often highly complex, unconsolidated and difficult to access.
Recently released, the Guide will be accompanied by complementary panel sessions in 2018 to equip potential investors with knowledge of the basic operations and products of life sciences companies as well as the risks and rewards.
The Guide is one of the three main components of the MTPConnect-funded ‘Comprehensive Global Investment Program for the Australian Life Sciences Sector – companies, investors and researchers’ project. AusBiotech-led Program aims to improve management and workforce skills. AusBiotech is working with consortium partners ASX, DibbsBarker, WE Buchan and KPMG, all of which bring extensive insight and experience in the life sciences to enhance the capability of the sector to engage with international markets and access global supply chains.
This venture has received funding through the MTPConnect Project Fund Program – a dollar-for-dollar matched program investing in big, bold ideas to improve the productivity, competitiveness and innovative capacity of Australia’s medical technology, biotechnology and pharmaceutical sector, supported by the Australian Government Industry Growth Centres Initiative.
The Guide can be found on the AusBiotech website.